BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

TEACHER

OncoOne

 

Company Info

Name /OncoOne

Address /Vienna, Austria

Website /www.oncone.com

Presenter

Name /Brent Meadows

Title /Chief Business Officer

Email /brent.meadows@oncoone.com

Telephone /+1 617 320 0041

Fax /+1 617 320 0041

Mobile /

Company Type

Biotechnology

About the Company

OncoOne has developed novel therapeutics for patients with solid tumors and immunology drugging a critical driver of innate immunity. Our founders were the first to identify and name oxMIF, the oxidized and disease-related isoform of the macrophage migration inhibitory factor (MIF). The first-in-human Phase I study of our lead asset ON203 for the treatment of solid tumors will begin early next year led by Harvard’s Massachusetts General Hospital Cancer Center. OncoOne’s lead immunology asset, ON104, also targets oxMIF with potential in RA, IBD, asthma, nephritis, as well as rare autoimmune diseases. OncoOne is actively seeking investors and a partner for the Asia-Pacific markets.

Brief Description of main products or services

 

Contact Person

Name /Brent Meadows

Email /brent.meadows@oncoone.com

Phone /+1 617 320 0041